Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Outlook Therapeutics, Inc. (OTLK)

1.01   -0.03 (-2.88%) 12-06 10:19
Open: 1.02 Pre. Close: 1.04
High: 1.0482 Low: 1.01
Volume: 56,517 Market Cap: 228(M)

Technical analysis

as of: 2022-12-06 9:50:10 AM
Overall:       
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Target: Six months: 1.31     One year: 1.41
Support: Support1: 0.98    Support2: 0.81
Resistance: Resistance1: 1.12    Resistance2: 1.21
Pivot: 1.04
Moving Average: MA(5): 1.05     MA(20): 1.05
MA(100): 1.15     MA(250): 1.33
MACD: MACD(12,26): -0.1     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 39.9     %D(3): 41.4
RSI: RSI(14): 45.9
52-week: High: 2.11  Low: 0.68
Average Vol(K): 3-Month: 468 (K)  10-Days: 292 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ OTLK ] has closed below upper band by 48.0%. Bollinger Bands are 51.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 9 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 1.08 - 1.09 1.09 - 1.09
Low: 0.99 - 0.99 0.99 - 1
Close: 1.03 - 1.04 1.04 - 1.05

Company Description

Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

Headline News

Thu, 01 Dec 2022
2022-12-01 | NDAQ:OTLK | Press Release | Outlook Therapeutics Inc. - Stockhouse

Wed, 23 Nov 2022
Outlook Therapeutics Awards 1.2 Million Stock Purchase Options to Top Management - Marketscreener.com

Thu, 03 Nov 2022
Is Outlook Therapeutics (NASDAQ:OTLK) Using Debt In A Risky Way? - Simply Wall St

Mon, 31 Oct 2022
Outlook Therapeutics (NASDAQ:OTLK) Coverage Initiated by Analysts at BTIG Research - MarketBeat

Fri, 28 Oct 2022
FDA accepts Outlook Therapeutics' biologics license application for wet AMD drug - Seeking Alpha

Thu, 06 Oct 2022
A director of Outlook Therapeutics, Inc. (NASDAQ:OTLK) purchases $19264.26 in stock. - Best Stocks

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 226 (M)
Shares Float 109 (M)
% Held by Insiders 51.5 (%)
% Held by Institutions 10.6 (%)
Shares Short 15,930 (K)
Shares Short P.Month 14,420 (K)

Stock Financials

EPS -0.33
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.09
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -109.4
Return on Equity (ttm) -396.7
Qtrly Rev. Growth 0
Gross Profit (p.s.) -0.18
Sales Per Share 0
EBITDA (p.s.) -0.28
Qtrly Earnings Growth 0
Operating Cash Flow -55 (M)
Levered Free Cash Flow -31 (M)

Stock Valuations

PE Ratio -3.26
PEG Ratio 0
Price to Book value 11.64
Price to Sales 0
Price to Cash Flow -4.28

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date 2019-03-17
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.